Ligand Pharmaceuticals Incorporated Stock Analysis

Ligand Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The book value of Ligand Pharmaceuticals was now reported as 44.84. The company has Price/Earnings To Growth (PEG) ratio of 1.53. Ligand Pharmaceuticals last dividend was issued on the 2nd of July 2010. The entity had 1603:1000 split on the 2nd of November 2022. Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company was incorporated in 1987 and is based in San Diego, California. Ligand Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 154 people. To find out more about Ligand Pharmaceuticals Incorporated contact John Higgins at 858 550 7500 or learn more at https://www.ligand.com.

Ligand Pharmaceuticals Investment Alerts

Ligand Pharmaceuticals Upcoming and Recent Events

Ligand Largest EPS Surprises

View All Earnings Estimates

Ligand Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Ligand Stock Institutional Investors

Note, although Ligand Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ligand Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.32 B.

Ligand Profitablity

The company has Profit Margin (PM) of 0.3 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.21 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.21.

Management Efficiency

Ligand Pharmaceuticals has return on total asset (ROA) of 0.013 % which means that it generated a profit of $0.013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.06 %, meaning that it created $0.06 on every $100 dollars invested by stockholders. Ligand Pharmaceuticals' management efficiency ratios could be used to measure how well Ligand Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ligand Pharmaceuticals' Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.07, whereas Return On Equity is forecasted to decline to 0.07. At present, Ligand Pharmaceuticals' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 385.2 M, whereas Other Current Assets are forecasted to decline to about 3.6 M.

Technical Drivers

As of the 29th of November, Ligand Pharmaceuticals secures the Mean Deviation of 1.85, risk adjusted performance of 0.0786, and Downside Deviation of 2.71. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Ligand Pharmaceuticals, as well as the relationship between them. Please verify Ligand Pharmaceuticals standard deviation, value at risk, kurtosis, as well as the relationship between the jensen alpha and semi variance to decide if Ligand Pharmaceuticals Incorporated is priced some-what accurately, providing market reflects its recent price of 121.47 per share. Given that Ligand Pharmaceuticals has jensen alpha of 0.0707, we recommend you to check Ligand Pharmaceuticals's last-minute market performance to make sure the company can sustain itself at a future point.

Ligand Pharmaceuticals Price Movement Analysis

Ligand Pharmaceuticals Insider Trading Activities

Ligand Pharmaceuticals Outstanding Bonds

Ligand Pharmaceuticals Predictive Daily Indicators

Ligand Pharmaceuticals Corporate Filings

Ligand Pharmaceuticals Forecast Models

Ligand Pharmaceuticals' time-series forecasting models are one of many Ligand Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ligand Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ligand Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ligand shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ligand Pharmaceuticals. By using and applying Ligand Stock analysis, traders can create a robust methodology for identifying Ligand entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ligand analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ligand analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Ligand Pharmaceuticals Incorporated stock analysis indicators help investors evaluate how Ligand Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ligand Pharmaceuticals shares will generate the highest return on investment. By understating and applying Ligand Pharmaceuticals stock analysis, traders can identify Ligand Pharmaceuticals position entry and exit signals to maximize returns.

When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.